Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy

ABSTRACT: Immunotherapy has revolutionized cancer treatment, yet many patients show non-sensitivity. Here, we collected treatment-naïve samples from 190 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy for proteome, phosphoproteome, and immunohistochemistry (IHC) analysis. Proteome-based stratification of ESCC identifies three proteomic subtypes (G-I-G-III) related to immunotherapy response and different molecular features, revealing patients with high mitochondrial complex I protein expression show sensitivity to anti-PD1 immunotherapy. High mitochondrial complex I protein expression of ESCC cells or patient-derived organoids increases sensitivity to CD8+ T cell-mediated killing in the co-culture systems. Phosphoproteomic data analysis reveal

SUBMITTER: Chen Ding 

PROVIDER: S-SCDT-10_1038-S44321-026-00413-9 | biostudies-other |

REPOSITORIES: biostudies-other